Cross-reactive serum and memory B-cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection.
Antibodies, Neutralizing
/ blood
Antibodies, Viral
/ blood
B-Lymphocytes
/ immunology
COVID-19
/ immunology
Cross Protection
/ immunology
Cross Reactions
/ immunology
Female
Humans
Immunologic Memory
/ immunology
Male
Severe acute respiratory syndrome-related coronavirus
/ immunology
SARS-CoV-2
/ immunology
Spike Glycoprotein, Coronavirus
/ immunology
Journal
Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555
Informations de publication
Date de publication:
19 05 2021
19 05 2021
Historique:
received:
18
09
2020
accepted:
08
04
2021
entrez:
20
5
2021
pubmed:
21
5
2021
medline:
1
6
2021
Statut:
epublish
Résumé
Pre-existing immunity to seasonal endemic coronaviruses could have profound consequences for antibody responses to SARS-CoV-2, induced from natural infection or vaccination. A first step to establish whether pre-existing responses can impact SARS-CoV-2 infection is to understand the nature and extent of cross-reactivity in humans to coronaviruses. Here we compare serum antibody and memory B cell responses to coronavirus spike proteins from pre-pandemic and SARS-CoV-2 convalescent donors using binding and functional assays. We show weak evidence of pre-existing SARS-CoV-2 cross-reactive serum antibodies in pre-pandemic donors. However, we find evidence of pre-existing cross-reactive memory B cells that are activated during SARS-CoV-2 infection. Monoclonal antibodies show varying degrees of cross-reactivity with betacoronaviruses, including SARS-CoV-1 and endemic coronaviruses. We identify one cross-reactive neutralizing antibody specific to the S2 subunit of the S protein. Our results suggest that pre-existing immunity to endemic coronaviruses should be considered in evaluating antibody responses to SARS-CoV-2.
Identifiants
pubmed: 34011939
doi: 10.1038/s41467-021-23074-3
pii: 10.1038/s41467-021-23074-3
pmc: PMC8134462
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
Spike Glycoprotein, Coronavirus
0
spike protein, SARS-CoV-2
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2938Subventions
Organisme : NIAID NIH HHS
ID : R01 AI073148
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI132317
Pays : United States
Organisme : NIAID NIH HHS
ID : R56 AI073148
Pays : United States
Commentaires et corrections
Type : UpdateOf
Références
Science. 2020 Dec 11;370(6522):1339-1343
pubmed: 33159009
Nat Med. 2020 Sep;26(9):1422-1427
pubmed: 32651581
Cell. 2016 Sep 8;166(6):1459-1470.e11
pubmed: 27610570
Nature. 2020 Aug;584(7821):353-363
pubmed: 32659783
Science. 2020 Aug 7;369(6504):731-736
pubmed: 32540900
Adv Virus Res. 2003;60:421-67
pubmed: 14689700
J Infect Dis. 2005 Jun 15;191(12):2033-7
pubmed: 15897988
J Struct Biol. 2005 Jul;151(1):41-60
pubmed: 15890530
Science. 2020 Aug 7;369(6504):643-650
pubmed: 32540902
Nature. 2013 Apr 25;496(7446):469-76
pubmed: 23552890
Nature. 2020 Aug;584(7821):437-442
pubmed: 32555388
Science. 2020 Mar 13;367(6483):1260-1263
pubmed: 32075877
Science. 2020 Aug 28;369(6507):1119-1123
pubmed: 32661058
Proc Natl Acad Sci U S A. 2017 Aug 29;114(35):E7348-E7357
pubmed: 28807998
Lancet. 2020 Feb 22;395(10224):565-574
pubmed: 32007145
Immunity. 2016 May 17;44(5):1215-26
pubmed: 27192579
J Struct Biol. 2009 Apr;166(1):95-102
pubmed: 19263523
Cell. 2020 Oct 1;183(1):158-168.e14
pubmed: 32979941
Cell. 2020 Jun 25;181(7):1489-1501.e15
pubmed: 32473127
Clin Infect Dis. 2020 Dec 03;:
pubmed: 33270134
J Immunol Methods. 2014 Jul;409:131-46
pubmed: 24291345
J Struct Biol. 2009 May;166(2):205-13
pubmed: 19374019
Sci Immunol. 2017 Aug 18;2(14):
pubmed: 28821561
Nat Commun. 2018 Sep 12;9(1):3693
pubmed: 30209313
Proc Natl Acad Sci U S A. 2012 Jul 24;109(30):E2083-90
pubmed: 22745174
Nature. 2016 Mar 3;531(7592):118-21
pubmed: 26935699
PLoS One. 2012;7(11):e50366
pubmed: 23185609
J Immunol. 2018 Aug 15;201(4):1315-1326
pubmed: 30006374
Cell. 2016 Apr 7;165(2):449-63
pubmed: 26949186
Science. 2009 Oct 9;326(5950):285-9
pubmed: 19729618
Nat Immunol. 2017 Apr;18(4):456-463
pubmed: 28192417
Nature. 2020 Aug;584(7819):115-119
pubmed: 32454513
Curr Opin Immunol. 2018 Aug;53:96-101
pubmed: 29730560
J Virol. 2015 Oct 14;90(1):76-91
pubmed: 26468542
Science. 2020 Aug 21;369(6506):956-963
pubmed: 32540903
JAMA. 2020 Feb 25;323(8):707-708
pubmed: 31971553
Immunity. 2020 Aug 18;53(2):442-455.e4
pubmed: 32668194
Proc Natl Acad Sci U S A. 2014 Dec 9;111(49):17624-9
pubmed: 25422458
J Immunol Methods. 2008 Jan 1;329(1-2):112-24
pubmed: 17996249
Science. 2020 Oct 2;370(6512):89-94
pubmed: 32753554
Nature. 2017 Aug 31;548(7669):597-601
pubmed: 28847005
J Med Virol. 2020 Apr;92(4):418-423
pubmed: 31967327
Immunity. 2017 Nov 21;47(5):990-1003.e9
pubmed: 29166592
Cell Rep Med. 2020 Oct 20;1(7):100126
pubmed: 33015650
Hum Vaccin Immunother. 2021 Jan 2;17(1):84-87
pubmed: 32678695
Cell Rep. 2018 Aug 21;24(8):1958-1966.e5
pubmed: 30134158
Cell. 2021 Apr 1;184(7):1858-1864.e10
pubmed: 33631096
Nature. 2014 May 1;509(7498):55-62
pubmed: 24590074
Nat Commun. 2020 Jun 1;11(1):2806
pubmed: 32483236
Cell. 2020 Aug 20;182(4):828-842.e16
pubmed: 32645326
Nat Commun. 2020 Sep 17;11(1):4704
pubmed: 32943637
Cell. 2016 Sep 8;166(6):1445-1458.e12
pubmed: 27610569
Nat Med. 2015 Nov;21(11):1332-6
pubmed: 26457756
Science. 2010 Aug 13;329(5993):856-61
pubmed: 20616233
J Struct Biol. 2012 Dec;180(3):519-30
pubmed: 23000701